BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 26967048)

  • 21. Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials.
    Fox K; Komajda M; Ford I; Robertson M; Böhm M; Borer JS; Steg PG; Tavazzi L; Tendera M; Ferrari R; Swedberg K
    Eur Heart J; 2013 Aug; 34(29):2263-70. PubMed ID: 23536611
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of Carvedilol, Ivabradine or their combination on exercise capacity in patients with Heart Failure (the CARVIVA HF trial).
    Volterrani M; Cice G; Caminiti G; Vitale C; D'Isa S; Perrone Filardi P; Acquistapace F; Marazzi G; Fini M; Rosano GM
    Int J Cardiol; 2011 Sep; 151(2):218-24. PubMed ID: 21764469
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of Ivabradine on Health-Related Quality of Life of Patients with Ischaemic Chronic Heart Failure.
    Sallam M; Al-Saadi T; Alshekaili L; Al-Zakwani I
    Curr Vasc Pharmacol; 2016; 14(5):481-486. PubMed ID: 27145825
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [New therapeutic approaches in heart failure].
    Hoppe UC
    Dtsch Med Wochenschr; 2011 Apr; 136(16):843-6. PubMed ID: 21448851
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of early treatment with ivabradine combined with beta-blockers versus beta-blockers alone in patients hospitalised with heart failure and reduced left ventricular ejection fraction (ETHIC-AHF): A randomised study.
    Hidalgo FJ; Anguita M; Castillo JC; Rodríguez S; Pardo L; Durán E; Sánchez JJ; Ferreiro C; Pan M; Mesa D; Delgado M; Ruiz M
    Int J Cardiol; 2016 Aug; 217():7-11. PubMed ID: 27167103
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ivabradine: Heart Failure and Beyond.
    Chaudhary R; Garg J; Krishnamoorthy P; Shah N; Lanier G; Martinez MW; Freudenberger R
    J Cardiovasc Pharmacol Ther; 2016 Jul; 21(4):335-43. PubMed ID: 26721645
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study.
    Swedberg K; Komajda M; Böhm M; Borer JS; Ford I; Dubost-Brama A; Lerebours G; Tavazzi L;
    Lancet; 2010 Sep; 376(9744):875-85. PubMed ID: 20801500
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of ''off-label'' use of ivabradine on exercise capacity, gas exchange, functional class, quality of life, and neurohormonal modulation in patients with ischemic chronic heart failure.
    Sarullo FM; Fazio G; Puccio D; Fasullo S; Paterna S; Novo S; Di Pasquale P
    J Cardiovasc Pharmacol Ther; 2010 Dec; 15(4):349-55. PubMed ID: 20940450
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prescribing patterns to optimize heart rate: analysis of 1,000 consecutive outpatient appointments to a single heart failure clinic over a 6-month period.
    Dierckx R; Cleland JG; Parsons S; Putzu P; Pellicori P; Dicken B; Boyalla V; Clark AL
    JACC Heart Fail; 2015 Mar; 3(3):224-30. PubMed ID: 25650369
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Heart rate reduction after heart transplantation with beta-blocker versus the selective If channel antagonist ivabradine.
    Doesch AO; Celik S; Ehlermann P; Frankenstein L; Zehelein J; Koch A; Katus HA; Dengler TJ
    Transplantation; 2007 Oct; 84(8):988-96. PubMed ID: 17989604
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Drug treatment for chronic heart failure with reduced ejection fraction].
    Rickenbacher P
    Ther Umsch; 2011 Feb; 68(2):71-9. PubMed ID: 21271537
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT).
    Swedberg K; Komajda M; Böhm M; Borer JS; Ford I; Tavazzi L
    Eur J Heart Fail; 2010 Jan; 12(1):75-81. PubMed ID: 19892778
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial.
    Kosmala W; Holland DJ; Rojek A; Wright L; Przewlocka-Kosmala M; Marwick TH
    J Am Coll Cardiol; 2013 Oct; 62(15):1330-8. PubMed ID: 23916925
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ivabradine for chronic heart failure?
    Drug Ther Bull; 2012 Oct; 50(10):117-20. PubMed ID: 23065752
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ivabradine in Heart Failure: The Representativeness of SHIFT (Systolic Heart Failure Treatment With the IF Inhibitor Ivabradine Trial) in a Broad Population of Patients With Chronic Heart Failure.
    Das D; Savarese G; Dahlström U; Fu M; Howlett J; Ezekowitz JA; Lund LH
    Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28903983
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ivabradine in combination with beta-blocker reduces symptoms and improves quality of life in elderly patients with stable angina pectoris: age-related results from the ADDITIONS study.
    Müller-Werdan U; Stöckl G; Ebelt H; Nuding S; Höpfner F; Werdan K;
    Exp Gerontol; 2014 Nov; 59():34-41. PubMed ID: 25193811
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nurse-coordinated collaborative disease management improves the quality of guideline-recommended heart failure therapy, patient-reported outcomes, and left ventricular remodelling.
    Güder G; Störk S; Gelbrich G; Brenner S; Deubner N; Morbach C; Wallenborn J; Berliner D; Ertl G; Angermann CE
    Eur J Heart Fail; 2015 Apr; 17(4):442-52. PubMed ID: 25727879
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of ivabradine on left ventricular remodelling after reperfused myocardial infarction: A pilot study.
    Gerbaud E; Montaudon M; Chasseriaud W; Gilbert S; Cochet H; Pucheu Y; Horovitz A; Bonnet J; Douard H; Coste P
    Arch Cardiovasc Dis; 2014 Jan; 107(1):33-41. PubMed ID: 24440004
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Heart rate reduction and exercise performance in recent onset heart failure with reduced ejection fraction: arguments for beta-blocker hypo-response.
    Verbrugge FH; Vrijsen J; Vercammen J; Grieten L; Dupont M; Mullens W
    Acta Cardiol; 2015 Oct; 70(5):565-72. PubMed ID: 26567816
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The efficacy of ivabradine in chronic heart failure (review)].
    Isakadze A; Makharadze T; Gvishiani M
    Georgian Med News; 2015 Apr; (241):44-9. PubMed ID: 25953938
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.